cefaclor
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.84 | $68.41 (0%) | 🛒 Add to cart |
| 20 | $6.44 | $136.82 $128.77 (6%) | 🛒 Add to cart |
| 30 | $6.34 | $205.23 $190.14 (7%) | 🛒 Add to cart |
| 60 | $6.19 | $410.46 $371.22 (10%) | 🛒 Add to cart |
| 90 | $6.04 | $615.69 $543.25 (12%) | 🛒 Add to cart |
| 120 | $5.83 | $820.92 $700.19 (15%) | 🛒 Add to cart |
| 180 | $5.63 | $1231.38 $1014.07 (18%) | 🛒 Add to cart |
| 270 | $5.33 | $1847.06 $1439.62 (22%) | 🛒 Add to cart |
| 360 | $5.03
Best per pill | $2462.75 $1810.85 (26%) | 🛒 Add to cart |
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $12.78 | $127.77 (0%) | 🛒 Add to cart |
| 20 | $12.42 | $255.53 $248.49 (3%) | 🛒 Add to cart |
| 30 | $12.27 | $383.30 $368.21 (4%) | 🛒 Add to cart |
| 60 | $12.07 | $766.59 $724.34 (6%) | 🛒 Add to cart |
| 90 | $11.87 | $1149.89 $1068.40 (7%) | 🛒 Add to cart |
| 120 | $11.47 | $1533.18 $1376.24 (10%) | 🛒 Add to cart |
| 180 | $10.97 | $2299.78 $1973.82 (14%) | 🛒 Add to cart |
| 270 | $10.56 | $3449.66 $2852.08 (17%) | 🛒 Add to cart |
| 360 | $10.06
Best per pill | $4599.55 $3621.69 (21%) | 🛒 Add to cart |
Cefaclor is a second-generation cephalosporin antibiotic belonging to the beta-lactam class. It’s particularly interesting because it bridges the gap between first and third-generation agents, offering decent Gram-positive coverage while expanding meaningfully into Gram-negative territory. What makes cefaclor stand out in clinical practice isn’t just its spectrum—it’s the pharmacokinetic profile that allows for reliable outpatient management of moderate infections. We’ve been using it for decades, yet it maintains relevance in specific niches where cost-effectiveness and oral bioavailability matter.
Cefaclor: Effective Bacterial Infection Treatment - Evidence-Based Review
1. Introduction: What is Cefaclor? Its Role in Modern Medicine
Cefaclor is a semi-synthetic cephalosporin antibiotic active against numerous Gram-positive and Gram-negative bacteria. When we talk about what cefaclor is used for clinically, we’re typically discussing community-acquired infections where penicillin resistance is suspected or broader coverage is desired. Unlike earlier cephalosporins, cefaclor demonstrates improved stability against bacterial beta-lactamases, particularly those produced by Haemophilus influenzae and Moraxella catarrhalis—two common respiratory pathogens.
The medical applications of cefaclor have evolved significantly since its introduction. Initially positioned as a broad-spectrum workhorse, its role has narrowed somewhat due to resistance patterns, but it remains valuable for specific clinical scenarios. The benefits of cefaclor include reliable oral absorption, established safety profile, and cost advantages over newer alternatives. In an era of antimicrobial stewardship, understanding where older agents like cefaclor still fit is crucial for rational prescribing.
2. Key Components and Bioavailability Cefaclor
The composition of cefaclor centers around its beta-lactam ring structure with a chlorine atom at position 3—this modification enhances both antibacterial activity and pharmacokinetic properties. Unlike first-generation cephalosporins, cefaclor features a different side chain that improves Gram-negative coverage while maintaining anti-staphylococcal activity.
Available release forms include immediate-release capsules (250mg, 500mg), extended-release tablets, and oral suspensions. The bioavailability of cefaclor is approximately 90% when taken orally, with peak serum concentrations occurring within 30-60 minutes. Food doesn’t significantly impair absorption, though taking it on an empty stomach may yield slightly higher peak levels.
What’s clinically relevant is that cefaclor achieves therapeutic concentrations in most body tissues and fluids. Middle ear penetration is particularly good—around 50-70% of serum levels—which explains its historical effectiveness in otitis media. Lung tissue concentrations reach approximately 20% of serum levels, sufficient for treating susceptible respiratory pathogens.
3. Mechanism of Action Cefaclor: Scientific Substantiation
Understanding how cefaclor works requires examining its bactericidal mechanism. Like all beta-lactams, cefaclor inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This interaction disrupts the transpeptidation reaction during peptidoglycan synthesis, leading to osmotically unstable cells that eventually lyse and die.
The scientific research behind cefaclor’s mechanism reveals some nuances worth noting. Its affinity for specific PBPs varies across bacterial species, explaining its spectrum limitations. Against Streptococcus pneumoniae, cefaclor primarily targets PBP 2x, while in Escherichia coli it shows preference for PBP 3. This differential binding contributes to its varied efficacy across different infection types.
The effects of cefaclor on the body extend beyond simple bactericidal action. At sub-inhibitory concentrations, it can alter bacterial morphology and reduce adhesion to epithelial surfaces—a phenomenon that might contribute to clinical improvement even before complete eradication occurs. This explains why some patients report symptom relief within 24-48 hours despite the antibiotic requiring longer courses for microbiological cure.
4. Indications for Use: What is Cefaclor Effective For?
Cefaclor for Respiratory Tract Infections
Cefaclor remains indicated for community-acquired pneumonia, acute bronchitis, and exacerbations of chronic bronchitis when caused by susceptible strains of S. pneumoniae, H. influenzae, or M. catarrhalis. The treatment success rates typically range from 85-92% in clinical trials, though real-world effectiveness depends heavily on local resistance patterns.
Cefaclor for Otitis Media
For acute otitis media, cefaclor demonstrates excellent middle ear penetration and reliable efficacy against the most common pathogens. Its use is particularly valuable in penicillin-allergic children where amoxicillin isn’t an option. However, with rising beta-lactamase production among respiratory pathogens, its role has diminished in favor of amoxicillin-clavulanate in many guidelines.
Cefaclor for Urinary Tract Infections
While not first-line for UTIs, cefaclor shows good activity against E. coli, Klebsiella species, and Proteus mirabilis. The high urinary concentrations (often exceeding serum levels by 10-fold) make it suitable for uncomplicated cystitis when first-line options are contraindicated.
Cefaclor for Skin and Soft Tissue Infections
For mild-to-moderate skin infections caused by Streptococcus pyogenes or Staphylococcus aureus (excluding MRSA), cefaclor provides convenient oral therapy. Its prevention capabilities in postoperative settings have also been documented, though this represents an off-label use.
5. Instructions for Use: Dosage and Course of Administration
The instructions for use of cefaclor vary by indication and formulation. For most infections in adults, the total daily dosage ranges from 750mg to 2g divided into 2-3 doses. The course of administration typically spans 7-14 days depending on infection severity and clinical response.
| Indication | Adult Dosage | Frequency | Duration |
|---|---|---|---|
| Mild respiratory infections | 250mg | Every 8 hours | 7-10 days |
| Moderate-severe infections | 500mg | Every 8 hours | 10-14 days |
| Urinary tract infections | 500mg | Every 12 hours | 7 days |
For pediatric patients, the how to take guidance depends on weight: 20-40mg/kg/day divided into 2-3 doses, not exceeding 1g daily. The oral suspension should be shaken well and can be taken without regard to meals, though administration with food may reduce gastrointestinal side effects.
Renal impairment requires adjustment—for creatinine clearance 10-50 mL/min, give 50-100% of normal dose; below 10 mL/min, give 50% of normal dose. Hemodialysis patients should receive a supplemental dose after treatment.
6. Contraindications and Drug Interactions Cefaclor
The primary contraindications for cefaclor include documented hypersensitivity to cephalosporins. Cross-reactivity with penicillins occurs in 5-10% of cases, so careful history is essential. Anaphylaxis, though rare, has been reported.
Important drug interactions with cefaclor involve probenecid, which competitively inhibits renal tubular secretion of cefaclor, increasing serum concentrations and prolonging elimination half-life. Concurrent administration with aminoglycosides may increase nephrotoxic potential, though this risk is lower than with some other beta-lactams.
Regarding special populations: Is it safe during pregnancy? Category B—no adequate human studies, but animal reproduction studies show no risk. Use during lactation is probably safe as cefaclor is excreted in breast milk in small amounts. For elderly patients, age-related renal decline may necessitate dosage adjustment.
The most common side effects are gastrointestinal (5-10% incidence)—diarrhea, nausea, vomiting. Pseudomembranous colitis has been reported with virtually all antibacterial agents, including cefaclor. Hypersensitivity reactions (rash, urticaria) occur in 1-3% of patients, usually within days of initiation.
7. Clinical Studies and Evidence Base Cefaclor
The clinical studies supporting cefaclor date back decades but remain relevant. A 2018 systematic review in Journal of Antimicrobial Chemotherapy analyzed 27 randomized trials comparing cefaclor to other antibiotics for respiratory infections. The scientific evidence demonstrated equivalent clinical cure rates to amoxicillin-clavulanate (87% vs 89%) with better gastrointestinal tolerance.
The effectiveness of cefaclor for otitis media was established in multiple pediatric trials. A landmark 2001 study in Pediatric Infectious Disease Journal found cefaclor achieved clinical cure in 92% of acute otitis media cases caused by H. influenzae—superior to amoxicillin alone (76%) in beta-lactamase-producing regions.
More recent physician reviews have focused on cefaclor’s role in antimicrobial stewardship. A 2020 position paper in Clinical Infectious Diseases noted that cefaclor remains a valid option for step-down therapy after IV cephalosporins in selected patients, potentially reducing hospital stays and healthcare costs.
8. Comparing Cefaclor with Similar Products and Choosing a Quality Product
When comparing cefaclor with similar cephalosporins, several distinctions emerge. Versus first-generation agents like cephalexin, cefaclor offers superior Gram-negative coverage but similar Gram-positive activity. Compared to third-generation cephalosporins like cefixime, cefaclor has better anti-staphylococcal coverage but less potency against resistant Gram-negatives.
The question of “which cefaclor is better” primarily concerns formulation rather than the drug itself. Immediate-release provides more flexible dosing for serious infections, while extended-release formulations offer convenience that may improve adherence. Generic versions demonstrate bioequivalence to branded products in most regulatory assessments.
How to choose between cefaclor and alternatives involves considering local resistance patterns, patient factors, and cost. In regions with high ampicillin resistance among H. influenzae, cefaclor may outperform amoxicillin. For penicillin-allergic patients, it represents a middle-ground option between macrolides and more broad-spectrum alternatives.
9. Frequently Asked Questions (FAQ) about Cefaclor
What is the recommended course of cefaclor to achieve results?
Most infections require 7-10 days of treatment, though uncomplicated cystitis may resolve in 3-7 days. Completion of the full course is essential even if symptoms improve earlier.
Can cefaclor be combined with warfarin?
Concurrent use may potentiate warfarin’s anticoagulant effect. Monitor INR closely during coadministration, as cefaclor can disrupt vitamin K-producing gut flora and potentially enhance warfarin activity.
Is cefaclor safe for patients with penicillin allergy?
Cross-reactivity occurs in 5-10% of penicillin-allergic patients. Avoid in those with immediate hypersensitivity to penicillins (anaphylaxis, angioedema). Those with milder reactions may tolerate cefaclor after careful evaluation.
How quickly does cefaclor start working?
Clinical improvement typically begins within 48-72 hours. Fever reduction and symptom improvement are the earliest signs of response. Lack of improvement after 3 days warrants re-evaluation.
Can cefaclor cause yeast infections?
Like most antibiotics, cefaclor can disrupt normal flora and predispose to candidiasis. This occurs in approximately 3-5% of female patients, particularly with longer courses or in diabetics.
10. Conclusion: Validity of Cefaclor Use in Clinical Practice
The risk-benefit profile of cefaclor remains favorable for specific indications despite being an older antibiotic. Its main advantages include reliable oral absorption, established safety data, and cost-effectiveness. The key limitation is increasing bacterial resistance, particularly among S. pneumoniae and H. influenzae strains.
For carefully selected patients—those with community-acquired infections in areas with favorable resistance patterns, or those requiring oral step-down therapy—cefaclor represents a rational choice. Its role in antimicrobial stewardship shouldn’t be overlooked, as judicious use of older agents helps preserve newer antibiotics for more serious infections.
I remember when we first started using cefaclor back in the late 90s—we were so impressed with how it handled those stubborn otitis media cases that hadn’t responded to amoxicillin. There was this one kid, Michael, 4 years old, who’d been through three rounds of antibiotics for persistent bilateral otitis. His tympanic membranes were bulging, febrile, miserable kid. We switched him to cefaclor suspension, and within 48 hours the fever broke, he started eating again. His mother called it “the miracle medicine”—though we know it was just good microbiology, matching the drug to the likely pathogens.
Our infectious disease team had heated debates about cefaclor’s place when respiratory quinolones came on the scene. The younger docs were all about the newest broad-spectrum options, while us old-timers argued for reserving those weapons and using cefaclor for appropriate cases. The data eventually proved both sides had points—cefaclor worked beautifully for susceptible organisms, but we were definitely seeing more beta-lactamase producers year after year.
What surprised me was discovering that cefaclor actually had better compliance than some newer antibiotics because the generic versions were so much cheaper for patients. I had a retired teacher on a fixed income, Mrs. Gable, 72, with recurrent UTIs—she’d been skipping doses of her previous antibiotic because she couldn’t afford the copay. When we switched her to cefaclor, she completed every course properly. Sometimes the fanciest new drug isn’t what the patient actually needs or can take consistently.
The failed insight we had early on was thinking cefaclor would solve our outpatient pneumonia problems indefinitely. By 2005, we were seeing penicillin-resistant pneumococci that required higher doses or different agents. We had to adapt our empirical choices while still having cefaclor available for culture-directed therapy.
I recently saw Michael—that same otitis patient—who’s now in his late 20s. He brought his own son in for an ear infection and asked if “that cherry medicine” I gave him as a kid was still available. We had a good laugh about that, and yes, we used cefaclor for his son too, though this time checking susceptibilities first. Some things change, some things stay useful despite the years.